argenex SE $ARGX Stock Position Lowered by BNP Paribas Financial Markets

BNP Paribas Financial Markets lessened its position in argenex SE (NASDAQ:ARGX) by 33.7% in the 4th quarter, Holdings Channel reports. The fund owned 70,744 shares of the company’s stock after selling 35,970 shares during the period. BNP Paribas Financial Markets’ holdings in argenex were worth $59,492,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Capital World Investors lifted its position in argenex by 0.4% in the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after buying an additional 8,422 shares in the last quarter. M&T Bank Corp grew its stake in argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after buying an additional 774,916 shares during the last quarter. Wellington Management Group LLP grew its stake in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after buying an additional 324,653 shares during the last quarter. Bank of America Corp DE boosted its holdings in argenex by 1.9% in the 3rd quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after purchasing an additional 6,259 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after purchasing an additional 250,278 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $802.17 on Wednesday. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The firm has a 50 day moving average price of $782.33 and a 200 day moving average price of $814.51. The stock has a market cap of $49.89 billion, a P/E ratio of 35.72, a P/E/G ratio of 1.32 and a beta of 0.47.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The firm had revenue of $1.31 billion for the quarter. Analysts predict that argenex SE will post 25.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARGX has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Robert W. Baird lifted their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Glj Research upgraded shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Finally, Guggenheim raised their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,019.50.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.